SA
Go ProLog In
ORIC
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
75
Score
10 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
10100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$15.00
+88.2%
Consensus
$22.00
+176.0%
Bull
$25.00
+213.7%
12-Month Target Range10 analysts
$15.00$22.00$25.00
Current $7.97Consensus
Current Price
$7.97
Upside to Consensus
$14.03

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-73.08%
EPS—
FY2028
Rev+389.74%
EPS—
FY2029
Rev+575.36%
EPS—

Earnings Surprises

Recent Analyst Actions

May 15, 2026Goldman Sachs
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
Target:$15.00
+79.9%from $8.34
Feb 24, 2026H.C. Wainwright
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright
Target:$25.00
+88.5%from $13.27
Feb 24, 2026Oppenheimer
Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC)
Target:$15.00
+28.1%from $11.71
Jan 7, 2026Piper Sandler
Oric Pharmaceuticals initiated with an Overweight at Piper Sandler
Target:$22.00
+170.3%from $8.14
Dec 8, 2025Wells Fargo
Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo
Target:$25.00
+127.3%from $11.00
Nov 14, 2025H.C. Wainwright
Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
Target:$23.00
+80.0%from $12.78
Sep 4, 2025Guggenheim
Oric Pharmaceuticals assumed with a Buy at Guggenheim
Target:$18.00
+69.8%from $10.60
May 6, 2025Oppenheimer
Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer
Target:$12.00
+138.1%from $5.04
Sep 5, 2024Stifel Nicolaus
Oric Pharmaceuticals initiated with a Buy at Stifel
Target:$20.00
+111.0%from $9.48
Mar 21, 2024H.C. Wainwright
ORIC Pharamceuticals (ORIC) PT Raised to $21 at H.C. Wainwright following 2023 results
Target:$21.00
+43.9%from $14.59
Mar 12, 2024Wedbush
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
Target:$20.00
+36.7%from $14.63
Mar 12, 2024Oppenheimer
ORIC Pharamceuticals (ORIC) PT Raised to $17 at Oppenheimer, 'Executing On Multiple Fronts'
Target:$17.00
+18.7%from $14.32
Apr 5, 2022Citigroup
ORIC Pharmaceuticals (ORIC) Stock: Why The Price Increased
Target:$7.00
+1.4%from $6.90

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance